Historical note and terminology
Mycophenolate mofetil is the semisynthetic morpholinoethyl ester of mycophenolate acid, which has been developed as an immunosuppressive agent to prevent rejection of transplanted organs. It was commercialized as CellCept by Hoffmann-La Roche. Mycophenolic acid was originally used to treat psoriasis in the 1970s. More recently, this agent has been used to treat several inflammatory conditions, including systemic lupus erythematosus, particularly in lupus nephritis. Currently it is in clinical trials for autoimmune myasthenia gravis, which will be the focus of this article. However, the knowledge of clinical pharmacology and safety of this drug is based on use in transplant patients, the only approved use.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.